losartan has been researched along with Ehlers-Danlos Syndrome in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Ehlers-Danlos Syndrome: A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubacher, N | 1 |
| Münger, J | 1 |
| Gorosabel, MC | 1 |
| Crabb, J | 1 |
| Ksiazek, AA | 1 |
| Caspar, SM | 1 |
| Bakker, ENTP | 1 |
| van Bavel, E | 1 |
| Ziegler, U | 1 |
| Carrel, T | 1 |
| Steinmann, B | 1 |
| Zeisberger, S | 1 |
| Meienberg, J | 1 |
| Matyas, G | 1 |
1 other study available for losartan and Ehlers-Danlos Syndrome
| Article | Year |
|---|---|
Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Tho | 2020 |